There are currently 1115 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
TReatment for ImmUne Mediated PathopHysiology
NCT04862221
Recruiting
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/28/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Register for Updates
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333
Recruiting
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF. Subjects will be randomized into one of three treatment groups in a 1:1:1
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: The Christ Hospital / The Linder Center for Research, Cincinnati, Ohio +1 locations
Conditions: Congestive Heart Failure
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608
Recruiting
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Clinical Study Site, Cincinnati, Ohio
Conditions: Non-Small Cell Lung Cancer
Register for Updates
BE WELL With Migraine: Brain Education and WELLness With Migraine
NCT05987592
Recruiting
The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Migraine
Register for Updates
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132
Recruiting
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
05/28/2025
Locations: Cincinnati Childrens Hospital, Cincinnati, Ohio
Conditions: Generalized Epidermolysis Bullosa Simplex
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Cincinnati, Ohio
Conditions: Neoplasms, Head and Neck
Register for Updates
Esprit BTK Post-Approval Study
NCT06656364
Recruiting
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Christ Hospital, Cincinnati, Ohio
Conditions: Chronic Limb-Threatening Ischemia
Register for Updates
Neonatal Platelet Transfusion Threshold Trial
NCT06676904
Recruiting
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Gender:
ALL
Ages:
Between 1 hour and 48 hours
Trial Updated:
05/28/2025
Locations: Cincinnati Children's Medical Center, Cincinnati, Ohio
Conditions: Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
Register for Updates
Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing
NCT05560477
Recruiting
The purpose of this clinical trial is to assess the safety and efficacy of AM3101 to facilitate meniscal repair and reduce the incidence of non-healing complications and morbidities associated with a failed meniscal repair. This is a prospective, randomized, controlled, double-blinded, multi-center study.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
05/27/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Meniscus Tear
Register for Updates
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
NCT05911568
Recruiting
TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Register for Updates
Real World Prostate Cancer Registry
NCT06355336
Recruiting
Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological features, stages, and disease biology. The treatment options are dependent on the disease stage, its features, and the patient's condition and preferences. The disease outcome also varies significantly d... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Cincinnati Cancer Advisors, Cincinnati, Ohio
Conditions: Prostate Cancer
Register for Updates
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Gender:
ALL
Ages:
Between 13 years and 90 years
Trial Updated:
05/27/2025
Locations: Oncology Hematology Care, Cincinnati, Ohio
Conditions: B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
Register for Updates